agil post strong beat-and-rais quarter
highlight core revenu growth strength across end
market geographi compani rais guidanc
expect core growth continu feel
somewhat conserv part agil strength come
macro environ part also impact innov
new product cycl agil recent success later bucket
keep us outperform rais estim
quick take quarter agil beat revenu ep
consensu driven strong core growth vs consensu
strength broad-bas across segment end market
academia/govt lead way pharma/biotech
pharma/biotech outlook posit bounc back timing-
america notabl strong
compani continu deliv agil agil initi
oper margin expand yoy twelfth consecut quarter
detail see varianc tabl exhibit
guidanc manag revis guidanc strong
quarter revenu increas midpoint
fx core ep increas midpoint
growth guidanc increas margin
expans expect vs previous
revenu project midpoint core
growth ep midpoint detail see guidanc
tabl exhibit
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud amort intang non-recur item
compani prioriti stock list
compani data secur llc estim reuter
report date estactualconsyr net incom pre-tax incom incom continu share analysisyr yrseq sale net bpsgross bpsr net bpssg net bpsoper bpspretax bpstax bpsnet bpsebitda bpssegment analysisyr yrseqlsag segment bpsgrowth bpsgrowth bpsgrowth bpsgross bpsoper bpsacg segment bpsgrowth bpsgrowth bpsgrowth bpsgross bpsoper bpsdgg segment bpsgrowth bpsgrowth bpsgrowth bpsgross bpsoper bpsconsolid growth bpstotal growth bpstotal growth bpstotal revenu bpssourc compani data factset secur llc estimatesin mm except epsactualfi end agil inc
priorcurrentchangepriorcurrentchangetot net incom pre-tax incom incom continu share margin analysi sale net bpsgross bpsr net bpssg net bpsoper bpspretax bpstax bpsnet bpsebitda bpssegment analysislsag segment bpsgrowth bpsgrowth bpsgrowth bpsgross bpsoper bpsacg segment bpsgrowth bpsgrowth bpsgrowth bpsgross bpsoper bpsdgg segment bpsgrowth bpsgrowth bpsgrowth bpsgross bpsoper bpsconsolid growth bpstotal growth bpstotal growth bpstotal revenu bpssourc compani data secur llc estimatesfi end mm except life scienc tool servic diagnost
growth fx fx fx fx ratesoper adjust adjust billingsnet interest incom keysight keysight billingstax share repurchas market comp cash flow compani press releas transcript secur llcagil real estat bill book incom cost sg along-term revenu growth top lsag acg increment margin lead oper margin increment margin lead oper margin unadjust adjust bill lsag acg adjust billingstax return repo dividend compani press releas transcript secur llc agil technolog inc
agil summari data fy end octob million except per gross oper interest inc exp pre-tax provis incom net non-gaap dilut share margin analysi sale net margin continu share analysislsag segment growth oper segment growth oper segment growth oper total growth growth growth revenu total net cash debt ttm flow capit free cash factset com secur llc estimatesincom statementchang analysi y/i life scienc tool servic diagnost
price target nc
price target dcf-base wacc termin noplat growth repres fy
ep estim think primari risk global macro deterior could hamper uptak
intuvo recent improv execut falter could shake investor recent willing award
agil higher multipl lastli corpor tax reform fail materi agil could stuck
agil solid momentum sever consecut quarter increment improv oper
result core growth margin tax rate free cash flow consist execut also bullish
agil intuvo product cycl could acceler growth materi fy particularli
industri end market remain strong final compani see signific benefit event
corpor tax reform return cash trap oversea
consum servic life scienc appli industri clinic market rel peer
compani high exposur appli end market high exposur emerg market
compani oper three segment life scienc appli market group lsag agil
crosslab group acg diagnost genom group dgg lsag provid analyt tool
ga liquid chromatographi mass spectrometri atom spectroscopi instrument
softwar acg provid servic consum agil instrument well instrument
competitor dgg provid diagnost genom tool particular strength anatom
patholog cytogenet array sequenc sampl prep
